Therapeutic Vaccines Market Size by Product, Technology, Vaccine Type, End-User, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2034

15.44%
CAGR (2026-2034)
98.07 USD Bn.
Forecast Market Size
323
Report Pages
145
Market Tables

Overview

Therapeutic Vaccines Market size was valued at USD 98.07 Bn in 2025, and the Therapeutic Vaccines Market revenue is expected to grow at a CAGR of 15.44% from 2026 to 2034, reaching nearly USD 357.08 Bn.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global  market dynamics, structure by identifying and analysing the market segments and project the global market size.

Therapeutic Vaccines Market Growth and Share AnalysisTherapeutic Vaccines Market Growth

To know about the Research Methodology :- Request Free Sample Report

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global market.

Global therapeutic vaccines market is fixed to witness great growth opportunities in recent times. This can be attributed to the increasing awareness of communicable diseases and new threats, cost-effectiveness of vaccines, development in new research techniques and growing demand, new target population and the emergence of developing markets. The major driving factor such as the increasing occurrence of cancer, cardiovascular diseases, HIV infection and several chronic diseases are boosting the market.

In addition, Increase in funding’s from the government for vaccine development and growing awareness among people for severe disease are the key factors escalating the growth of global therapeutic vaccines market. With the increasing demand for different types of vaccines to be introduced into the market, there is one restraint to this situation. The vaccine research requires huge capital to be invested and a lot of time to be spent.

Therapeutic Vaccines Market Segmentation Analysis

Based on Product, The Global Therapeutic Vaccines Market can be segmented, by product type, into the following 4 key subsegments: addiction vaccines, autoimmune disease vaccines, infectious disease vaccines, and neurological disease vaccines. Each represent a niche strategy - using immune-based therapies to manage disease or shape the disease path.

The autoimmune disease vaccines segment, however, is leading all other segments. This is mainly due to the increasing incidence of autoimmune diseases, including rheumatoid arthritis, type I diabetes mellitus, and multiple sclerosis, creating a rise in immune-modulating treatment that users can use as an alternative long-term treatment.

Region-wise, North America represents developed regional markets for therapeutic vaccines and is anticipated to see the rapid growth in the upcoming years. The US is by far the leading therapeutic vaccine market by country in North America. The US market is predictable to grow at the highest CAGR during the forecast period. This growth is mainly owing to the well-developed healthcare infrastructure and increases in research and development on a therapeutic vaccine. Additionally, the disposable income and reimbursement of life-threatening diseases are very high in this region which promotes the growth of global therapeutic vaccine market. Europe was the second largest regional market and is estimated to show significant growth in the years to come. This growth is mainly as of increase in a number of patients diagnosed with cancer.

Therapeutic Vaccines Market Recent Development:

Date Company Development Impact
22 December 2025 Sanofi Sanofi entered into a definitive agreement to acquire Dynavax Technologies for approximately $2.2 billion to expand its portfolio of adult and targeted vaccines. The acquisition significantly strengthens Sanofi's commercial footprint in advanced adult immunizations and adjuvanted therapeutic vaccine technology platforms.
15 January 2026 ErVimmune ErVimmune successfully closed a €17 million Series A funding round to advance its lead therapeutic cancer vaccine candidate, ErVac01, into Phase I clinical trials. The funding accelerates the clinical validation of novel targeted cancer immunotherapies directed at endogenous retrovirus tumor antigens.
24 March 2026 Denteric Denteric secured FDA Investigational New Drug (IND) clearance for GPV381, a first-in-class therapeutic vaccine targeting gingipain-driven inflammation in chronic periodontitis. This milestone marks a critical expansion of therapeutic vaccines into chronic inflammatory and non-oncology oral health conditions.
22 June 2026 Transgene Transgene expanded its myvac® platform into non-small cell lung cancer by launching development for TG4070, an individualized neoantigen therapeutic vaccine. The program broadens personalized viral-vector therapeutic vaccines into high-prevalence solid tumor markets to improve progression-free survival.
24 August 2026 BriaCell Therapeutics BriaCell Therapeutics advanced its off-the-shelf personalized melanoma immunotherapy vaccine candidate, Bria-MEL+™, into target clinical development. The development enhances cell-based therapeutic vaccine accessibility by eliminating the need for complex patient-specific manufacturing processes.

Scope Global Therapeutic Vaccines Market: Inquire before buying

Global Therapeutic Vaccines Market
Report Coverage Details
Base Year: 2025 Forecast Period: 2026-2034
Historical Data: 2020 to 2025 Market Size in 2025: USD 98.07 Bn.
Forecast Period 2026 to 2034 CAGR: 15.44% Market Size in 2034: USD 357.08 Bn.
Segments Covered: by Product Addiction Vaccines
Autoimmune Disease Vaccines
Infectious Disease Vaccines
Neurological Disease Vaccines
by Technology Autologous vaccines
Allogeneic vaccines
by Vaccine Type Tumour Cell Vaccines
Antigen/Peptide-based Vaccines
Dendritic Cell Vaccines
DNA Vaccines
RNA/mRNA-based Vaccines
Virus-like Particle (VLP) / Vector-based Vaccines
Others
by End-User Hospitals
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Therapeutic Vaccines Market, by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key players operating in Global Therapeutic Vaccines Market

1. Sanofi-Pasteur
2. Cytos Biotechnology AG
3. Intellect Neurosciences
4. Agenus Inc.
5. Celtic Pharma,
6. Novartis
7. Dendreon Corp.
8. Pfizer
9. Transgene
10. Antigenics
11. Argos Therapeutics
12. Bavarian Nordic
13. Biovest International
14. Celldex Therapeutics
15. Cel-Sci
16. Curevac
17. GlaxoSmithKline
18. Merck & Co.
19. Vaccinogen Inc.
20. Affiris
21. Medimmune, LLC

Frequently Asked Questions:

1. Which region has the largest share in Global Therapeutic Vaccines Market?
Ans: Asia Pacific region holds the highest share in 2025.

2. What is the growth rate of Global Therapeutic Vaccines Market?
Ans: The Global Therapeutic Vaccines Market is growing at a CAGR of 15.44% during forecasting period 2026-2034.

3. What is scope of the Global Therapeutic Vaccines Market report?
Ans: Global Therapeutic Vaccines Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. What is the study period of market?
Ans: The Global Market is studied from 2020 to 2034.

Table of Contents

1. Therapeutic Vaccines Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global Therapeutic Vaccines Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Landscape 2.3. Key Players Benchmarking 2.3.1. Company Name 2.3.2. Business Segment 2.3.3. End-user Segment 2.3.4. Revenue (2025) 2.3.5. Company Locations 2.4. Leading Therapeutic Vaccines Market Companies, by market capitalization 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 3. Therapeutic Vaccines Market: Dynamics 3.1. Therapeutic Vaccines Market Trends by Region 3.1.1. North America Therapeutic Vaccines Market Trends 3.1.2. Europe Therapeutic Vaccines Market Trends 3.1.3. Asia Pacific Therapeutic Vaccines Market Trends 3.1.4. Middle East and Africa Therapeutic Vaccines Market Trends 3.1.5. South America Therapeutic Vaccines Market Trends 3.2. Therapeutic Vaccines Market Dynamics by Region 3.2.1. North America 3.2.1.1. North America Therapeutic Vaccines Market Drivers 3.2.1.2. North America Therapeutic Vaccines Market Restraints 3.2.1.3. North America Therapeutic Vaccines Market Opportunities 3.2.1.4. North America Therapeutic Vaccines Market Challenges 3.2.2. Europe 3.2.2.1. Europe Therapeutic Vaccines Market Drivers 3.2.2.2. Europe Therapeutic Vaccines Market Restraints 3.2.2.3. Europe Therapeutic Vaccines Market Opportunities 3.2.2.4. Europe Therapeutic Vaccines Market Challenges 3.2.3. Asia Pacific 3.2.3.1. Asia Pacific Therapeutic Vaccines Market Drivers 3.2.3.2. Asia Pacific Therapeutic Vaccines Market Restraints 3.2.3.3. Asia Pacific Therapeutic Vaccines Market Opportunities 3.2.3.4. Asia Pacific Therapeutic Vaccines Market Challenges 3.2.4. Middle East and Africa 3.2.4.1. Middle East and Africa Therapeutic Vaccines Market Drivers 3.2.4.2. Middle East and Africa Therapeutic Vaccines Market Restraints 3.2.4.3. Middle East and Africa Therapeutic Vaccines Market Opportunities 3.2.4.4. Middle East and Africa Therapeutic Vaccines Market Challenges 3.2.5. South America 3.2.5.1. South America Therapeutic Vaccines Market Drivers 3.2.5.2. South America Therapeutic Vaccines Market Restraints 3.2.5.3. South America Therapeutic Vaccines Market Opportunities 3.2.5.4. South America Therapeutic Vaccines Market Challenges 3.3. PORTER's Five Forces Analysis 3.4. PESTLE Analysis 3.5. Technology Roadmap 3.6. Regulatory Landscape by Region 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Middle East and Africa 3.6.5. South America 3.7. Key Opinion Leader Analysis in the Therapeutic Vaccines Market 3.8. Analysis of Government Schemes and Initiatives For Global Industry 3.9. Therapeutic Vaccines Market Trade Analysis 3.10. The Global Pandemic Impact on Therapeutic Vaccines Market 4. Therapeutic Vaccines Market: Global Market Size and Forecast by Segmentation (in USD Billion) 2025-2034 4.1. Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 4.1.1. Addiction Vaccines 4.1.2. Autoimmune Disease Vaccines 4.1.3. Infectious Disease Vaccines 4.1.4. Neurological Disease Vaccines 4.2. Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 4.2.1. Autologous vaccines 4.2.2. Allogeneic vaccines 4.3. Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 4.3.1. Tumour Cell Vaccines 4.3.2. Antigen/Peptide-based Vaccines 4.3.3. Dendritic Cell Vaccines 4.3.4. DNA Vaccines 4.3.5. RNA/mRNA-based Vaccines 4.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 4.3.7. Others 4.4. Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 4.4.1. Hospitals 4.4.2. Hospital Pharmacies 4.4.3. Retail Pharmacies 4.4.4. Online Pharmacies 4.5. Therapeutic Vaccines Market Size and Forecast, by Region (2025-2034) 4.5.1. North America 4.5.2. Europe 4.5.3. Asia Pacific 4.5.4. Middle East and Africa 4.5.5. South America 5. North America Therapeutic Vaccines Market Size and Forecast by Segmentation (in USD Billion) 2025-2034 5.1. North America Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 5.1.1. Addiction Vaccines 5.1.2. Autoimmune Disease Vaccines 5.1.3. Infectious Disease Vaccines 5.1.4. Neurological Disease Vaccines 5.2. North America Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 5.2.1. Autologous vaccines 5.2.2. Allogeneic vaccines 5.3. North America Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 5.3.1. Tumour Cell Vaccines 5.3.2. Antigen/Peptide-based Vaccines 5.3.3. Dendritic Cell Vaccines 5.3.4. DNA Vaccines 5.3.5. RNA/mRNA-based Vaccines 5.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 5.3.7. Others 5.4. North America Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 5.4.1. Hospitals 5.4.2. Hospital Pharmacies 5.4.3. Retail Pharmacies 5.4.4. Online Pharmacies 5.5. North America Therapeutic Vaccines Market Size and Forecast, by Country (2025-2034) 5.5.1. United States 5.5.1.1. United States Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 5.5.1.1.1. Addiction Vaccines 5.5.1.1.2. Autoimmune Disease Vaccines 5.5.1.1.3. Infectious Disease Vaccines 5.5.1.1.4. Neurological Disease Vaccines 5.5.1.2. United States Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 5.5.1.2.1. Autologous vaccines 5.5.1.2.2. Allogeneic vaccines 5.5.1.3. United States Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 5.5.1.3.1. Tumour Cell Vaccines 5.5.1.3.2. Antigen/Peptide-based Vaccines 5.5.1.3.3. Dendritic Cell Vaccines 5.5.1.3.4. DNA Vaccines 5.5.1.3.5. RNA/mRNA-based Vaccines 5.5.1.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 5.5.1.3.7. Others 5.5.1.4. United States Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 5.5.1.4.1. Hospitals 5.5.1.4.2. Hospital Pharmacies 5.5.1.4.3. Retail Pharmacies 5.5.1.4.4. Online Pharmacies 5.5.2. Canada 5.5.2.1. Canada Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 5.5.2.1.1. Addiction Vaccines 5.5.2.1.2. Autoimmune Disease Vaccines 5.5.2.1.3. Infectious Disease Vaccines 5.5.2.1.4. Neurological Disease Vaccines 5.5.2.2. Canada Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 5.5.2.2.1. Autologous vaccines 5.5.2.2.2. Allogeneic vaccines 5.5.2.3. Canada Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 5.5.2.3.1. Tumour Cell Vaccines 5.5.2.3.2. Antigen/Peptide-based Vaccines 5.5.2.3.3. Dendritic Cell Vaccines 5.5.2.3.4. DNA Vaccines 5.5.2.3.5. RNA/mRNA-based Vaccines 5.5.2.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 5.5.2.3.7. Others 5.5.2.4. Canada Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 5.5.2.4.1. Hospitals 5.5.2.4.2. Hospital Pharmacies 5.5.2.4.3. Retail Pharmacies 5.5.2.4.4. Online Pharmacies 5.5.3. Mexico 5.5.3.1. Mexico Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 5.5.3.1.1. Addiction Vaccines 5.5.3.1.2. Autoimmune Disease Vaccines 5.5.3.1.3. Infectious Disease Vaccines 5.5.3.1.4. Neurological Disease Vaccines 5.5.3.2. Mexico Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 5.5.3.2.1. Autologous vaccines 5.5.3.2.2. Allogeneic vaccines 5.5.3.3. Mexico Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 5.5.3.3.1. Tumour Cell Vaccines 5.5.3.3.2. Antigen/Peptide-based Vaccines 5.5.3.3.3. Dendritic Cell Vaccines 5.5.3.3.4. DNA Vaccines 5.5.3.3.5. RNA/mRNA-based Vaccines 5.5.3.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 5.5.3.3.7. Others 5.5.3.4. Mexico Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 5.5.3.4.1. Hospitals 5.5.3.4.2. Hospital Pharmacies 5.5.3.4.3. Retail Pharmacies 5.5.3.4.4. Online Pharmacies 6. Europe Therapeutic Vaccines Market Size and Forecast by Segmentation (in USD Billion) 2025-2034 6.1. Europe Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.1.1. Addiction Vaccines 6.1.2. Autoimmune Disease Vaccines 6.1.3. Infectious Disease Vaccines 6.1.4. Neurological Disease Vaccines 6.2. Europe Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.2.1. Autologous vaccines 6.2.2. Allogeneic vaccines 6.3. Europe Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.3.1. Tumour Cell Vaccines 6.3.2. Antigen/Peptide-based Vaccines 6.3.3. Dendritic Cell Vaccines 6.3.4. DNA Vaccines 6.3.5. RNA/mRNA-based Vaccines 6.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.3.7. Others 6.4. Europe Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.4.1. Hospitals 6.4.2. Hospital Pharmacies 6.4.3. Retail Pharmacies 6.4.4. Online Pharmacies 6.5. Europe Therapeutic Vaccines Market Size and Forecast, by Country (2025-2034) 6.5.1. United Kingdom 6.5.1.1. United Kingdom Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.1.1.1. Addiction Vaccines 6.5.1.1.2. Autoimmune Disease Vaccines 6.5.1.1.3. Infectious Disease Vaccines 6.5.1.1.4. Neurological Disease Vaccines 6.5.1.2. United Kingdom Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.1.2.1. Autologous vaccines 6.5.1.2.2. Allogeneic vaccines 6.5.1.3. United Kingdom Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.1.3.1. Tumour Cell Vaccines 6.5.1.3.2. Antigen/Peptide-based Vaccines 6.5.1.3.3. Dendritic Cell Vaccines 6.5.1.3.4. DNA Vaccines 6.5.1.3.5. RNA/mRNA-based Vaccines 6.5.1.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.1.3.7. Others 6.5.1.4. United Kingdom Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.1.4.1. Hospitals 6.5.1.4.2. Hospital Pharmacies 6.5.1.4.3. Retail Pharmacies 6.5.1.4.4. Online Pharmacies 6.5.2. France 6.5.2.1. France Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.2.1.1. Addiction Vaccines 6.5.2.1.2. Autoimmune Disease Vaccines 6.5.2.1.3. Infectious Disease Vaccines 6.5.2.1.4. Neurological Disease Vaccines 6.5.2.2. France Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.2.2.1. Autologous vaccines 6.5.2.2.2. Allogeneic vaccines 6.5.2.3. France Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.2.3.1. Tumour Cell Vaccines 6.5.2.3.2. Antigen/Peptide-based Vaccines 6.5.2.3.3. Dendritic Cell Vaccines 6.5.2.3.4. DNA Vaccines 6.5.2.3.5. RNA/mRNA-based Vaccines 6.5.2.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.2.3.7. Others 6.5.2.4. France Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.2.4.1. Hospitals 6.5.2.4.2. Hospital Pharmacies 6.5.2.4.3. Retail Pharmacies 6.5.2.4.4. Online Pharmacies 6.5.3. Germany 6.5.3.1. Germany Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.3.1.1. Addiction Vaccines 6.5.3.1.2. Autoimmune Disease Vaccines 6.5.3.1.3. Infectious Disease Vaccines 6.5.3.1.4. Neurological Disease Vaccines 6.5.3.2. Germany Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.3.2.1. Autologous vaccines 6.5.3.2.2. Allogeneic vaccines 6.5.3.3. Germany Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.3.3.1. Tumour Cell Vaccines 6.5.3.3.2. Antigen/Peptide-based Vaccines 6.5.3.3.3. Dendritic Cell Vaccines 6.5.3.3.4. DNA Vaccines 6.5.3.3.5. RNA/mRNA-based Vaccines 6.5.3.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.3.3.7. Others 6.5.3.4. Germany Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.3.4.1. Hospitals 6.5.3.4.2. Hospital Pharmacies 6.5.3.4.3. Retail Pharmacies 6.5.3.4.4. Online Pharmacies 6.5.4. Italy 6.5.4.1. Italy Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.4.1.1. Addiction Vaccines 6.5.4.1.2. Autoimmune Disease Vaccines 6.5.4.1.3. Infectious Disease Vaccines 6.5.4.1.4. Neurological Disease Vaccines 6.5.4.2. Italy Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.4.2.1. Autologous vaccines 6.5.4.2.2. Allogeneic vaccines 6.5.4.3. Italy Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.4.3.1. Tumour Cell Vaccines 6.5.4.3.2. Antigen/Peptide-based Vaccines 6.5.4.3.3. Dendritic Cell Vaccines 6.5.4.3.4. DNA Vaccines 6.5.4.3.5. RNA/mRNA-based Vaccines 6.5.4.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.4.3.7. Others 6.5.4.4. Italy Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.4.4.1. Hospitals 6.5.4.4.2. Hospital Pharmacies 6.5.4.4.3. Retail Pharmacies 6.5.4.4.4. Online Pharmacies 6.5.5. Spain 6.5.5.1. Spain Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.5.1.1. Addiction Vaccines 6.5.5.1.2. Autoimmune Disease Vaccines 6.5.5.1.3. Infectious Disease Vaccines 6.5.5.1.4. Neurological Disease Vaccines 6.5.5.2. Spain Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.5.2.1. Autologous vaccines 6.5.5.2.2. Allogeneic vaccines 6.5.5.3. Spain Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.5.3.1. Tumour Cell Vaccines 6.5.5.3.2. Antigen/Peptide-based Vaccines 6.5.5.3.3. Dendritic Cell Vaccines 6.5.5.3.4. DNA Vaccines 6.5.5.3.5. RNA/mRNA-based Vaccines 6.5.5.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.5.3.7. Others 6.5.5.4. Spain Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.5.4.1. Hospitals 6.5.5.4.2. Hospital Pharmacies 6.5.5.4.3. Retail Pharmacies 6.5.5.4.4. Online Pharmacies 6.5.6. Sweden 6.5.6.1. Sweden Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.6.1.1. Addiction Vaccines 6.5.6.1.2. Autoimmune Disease Vaccines 6.5.6.1.3. Infectious Disease Vaccines 6.5.6.1.4. Neurological Disease Vaccines 6.5.6.2. Sweden Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.6.2.1. Autologous vaccines 6.5.6.2.2. Allogeneic vaccines 6.5.6.3. Sweden Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.6.3.1. Tumour Cell Vaccines 6.5.6.3.2. Antigen/Peptide-based Vaccines 6.5.6.3.3. Dendritic Cell Vaccines 6.5.6.3.4. DNA Vaccines 6.5.6.3.5. RNA/mRNA-based Vaccines 6.5.6.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.6.3.7. Others 6.5.6.4. Sweden Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.6.4.1. Hospitals 6.5.6.4.2. Hospital Pharmacies 6.5.6.4.3. Retail Pharmacies 6.5.6.4.4. Online Pharmacies 6.5.7. Austria 6.5.7.1. Austria Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.7.1.1. Addiction Vaccines 6.5.7.1.2. Autoimmune Disease Vaccines 6.5.7.1.3. Infectious Disease Vaccines 6.5.7.1.4. Neurological Disease Vaccines 6.5.7.2. Austria Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.7.2.1. Autologous vaccines 6.5.7.2.2. Allogeneic vaccines 6.5.7.3. Austria Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.7.3.1. Tumour Cell Vaccines 6.5.7.3.2. Antigen/Peptide-based Vaccines 6.5.7.3.3. Dendritic Cell Vaccines 6.5.7.3.4. DNA Vaccines 6.5.7.3.5. RNA/mRNA-based Vaccines 6.5.7.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.7.3.7. Others 6.5.7.4. Austria Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.7.4.1. Hospitals 6.5.7.4.2. Hospital Pharmacies 6.5.7.4.3. Retail Pharmacies 6.5.7.4.4. Online Pharmacies 6.5.8. Rest of Europe 6.5.8.1. Rest of Europe Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 6.5.8.1.1. Addiction Vaccines 6.5.8.1.2. Autoimmune Disease Vaccines 6.5.8.1.3. Infectious Disease Vaccines 6.5.8.1.4. Neurological Disease Vaccines 6.5.8.2. Rest of Europe Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 6.5.8.2.1. Autologous vaccines 6.5.8.2.2. Allogeneic vaccines 6.5.8.3. Rest of Europe Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 6.5.8.3.1. Tumour Cell Vaccines 6.5.8.3.2. Antigen/Peptide-based Vaccines 6.5.8.3.3. Dendritic Cell Vaccines 6.5.8.3.4. DNA Vaccines 6.5.8.3.5. RNA/mRNA-based Vaccines 6.5.8.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 6.5.8.3.7. Others 6.5.8.4. Rest of Europe Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 6.5.8.4.1. Hospitals 6.5.8.4.2. Hospital Pharmacies 6.5.8.4.3. Retail Pharmacies 6.5.8.4.4. Online Pharmacies 7. Asia Pacific Therapeutic Vaccines Market Size and Forecast by Segmentation (in USD Billion) 2025-2034 7.1. Asia Pacific Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.1.1. Addiction Vaccines 7.1.2. Autoimmune Disease Vaccines 7.1.3. Infectious Disease Vaccines 7.1.4. Neurological Disease Vaccines 7.2. Asia Pacific Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.2.1. Autologous vaccines 7.2.2. Allogeneic vaccines 7.3. Asia Pacific Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.3.1. Tumour Cell Vaccines 7.3.2. Antigen/Peptide-based Vaccines 7.3.3. Dendritic Cell Vaccines 7.3.4. DNA Vaccines 7.3.5. RNA/mRNA-based Vaccines 7.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.3.7. Others 7.4. Asia Pacific Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.4.1. Hospitals 7.4.2. Hospital Pharmacies 7.4.3. Retail Pharmacies 7.4.4. Online Pharmacies 7.5. Asia Pacific Therapeutic Vaccines Market Size and Forecast, by Country (2025-2034) 7.5.1. China 7.5.1.1. China Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.1.1.1. Addiction Vaccines 7.5.1.1.2. Autoimmune Disease Vaccines 7.5.1.1.3. Infectious Disease Vaccines 7.5.1.1.4. Neurological Disease Vaccines 7.5.1.2. China Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.1.2.1. Autologous vaccines 7.5.1.2.2. Allogeneic vaccines 7.5.1.3. China Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.1.3.1. Tumour Cell Vaccines 7.5.1.3.2. Antigen/Peptide-based Vaccines 7.5.1.3.3. Dendritic Cell Vaccines 7.5.1.3.4. DNA Vaccines 7.5.1.3.5. RNA/mRNA-based Vaccines 7.5.1.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.1.3.7. Others 7.5.1.4. China Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.1.4.1. Hospitals 7.5.1.4.2. Hospital Pharmacies 7.5.1.4.3. Retail Pharmacies 7.5.1.4.4. Online Pharmacies 7.5.2. S Korea 7.5.2.1. S Korea Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.2.1.1. Addiction Vaccines 7.5.2.1.2. Autoimmune Disease Vaccines 7.5.2.1.3. Infectious Disease Vaccines 7.5.2.1.4. Neurological Disease Vaccines 7.5.2.2. S Korea Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.2.2.1. Autologous vaccines 7.5.2.2.2. Allogeneic vaccines 7.5.2.3. S Korea Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.2.3.1. Tumour Cell Vaccines 7.5.2.3.2. Antigen/Peptide-based Vaccines 7.5.2.3.3. Dendritic Cell Vaccines 7.5.2.3.4. DNA Vaccines 7.5.2.3.5. RNA/mRNA-based Vaccines 7.5.2.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.2.3.7. Others 7.5.2.4. S Korea Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.2.4.1. Hospitals 7.5.2.4.2. Hospital Pharmacies 7.5.2.4.3. Retail Pharmacies 7.5.2.4.4. Online Pharmacies 7.5.3. Japan 7.5.3.1. Japan Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.3.1.1. Addiction Vaccines 7.5.3.1.2. Autoimmune Disease Vaccines 7.5.3.1.3. Infectious Disease Vaccines 7.5.3.1.4. Neurological Disease Vaccines 7.5.3.2. Japan Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.3.2.1. Autologous vaccines 7.5.3.2.2. Allogeneic vaccines 7.5.3.3. Japan Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.3.3.1. Tumour Cell Vaccines 7.5.3.3.2. Antigen/Peptide-based Vaccines 7.5.3.3.3. Dendritic Cell Vaccines 7.5.3.3.4. DNA Vaccines 7.5.3.3.5. RNA/mRNA-based Vaccines 7.5.3.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.3.3.7. Others 7.5.3.4. Japan Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.3.4.1. Hospitals 7.5.3.4.2. Hospital Pharmacies 7.5.3.4.3. Retail Pharmacies 7.5.3.4.4. Online Pharmacies 7.5.4. India 7.5.4.1. India Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.4.1.1. Addiction Vaccines 7.5.4.1.2. Autoimmune Disease Vaccines 7.5.4.1.3. Infectious Disease Vaccines 7.5.4.1.4. Neurological Disease Vaccines 7.5.4.2. India Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.4.2.1. Autologous vaccines 7.5.4.2.2. Allogeneic vaccines 7.5.4.3. India Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.4.3.1. Tumour Cell Vaccines 7.5.4.3.2. Antigen/Peptide-based Vaccines 7.5.4.3.3. Dendritic Cell Vaccines 7.5.4.3.4. DNA Vaccines 7.5.4.3.5. RNA/mRNA-based Vaccines 7.5.4.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.4.3.7. Others 7.5.4.4. India Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.4.4.1. Hospitals 7.5.4.4.2. Hospital Pharmacies 7.5.4.4.3. Retail Pharmacies 7.5.4.4.4. Online Pharmacies 7.5.5. Australia 7.5.5.1. Australia Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.5.1.1. Addiction Vaccines 7.5.5.1.2. Autoimmune Disease Vaccines 7.5.5.1.3. Infectious Disease Vaccines 7.5.5.1.4. Neurological Disease Vaccines 7.5.5.2. Australia Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.5.2.1. Autologous vaccines 7.5.5.2.2. Allogeneic vaccines 7.5.5.3. Australia Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.5.3.1. Tumour Cell Vaccines 7.5.5.3.2. Antigen/Peptide-based Vaccines 7.5.5.3.3. Dendritic Cell Vaccines 7.5.5.3.4. DNA Vaccines 7.5.5.3.5. RNA/mRNA-based Vaccines 7.5.5.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.5.3.7. Others 7.5.5.4. Australia Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.5.4.1. Hospitals 7.5.5.4.2. Hospital Pharmacies 7.5.5.4.3. Retail Pharmacies 7.5.5.4.4. Online Pharmacies 7.5.6. Indonesia 7.5.6.1. Indonesia Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.6.1.1. Addiction Vaccines 7.5.6.1.2. Autoimmune Disease Vaccines 7.5.6.1.3. Infectious Disease Vaccines 7.5.6.1.4. Neurological Disease Vaccines 7.5.6.2. Indonesia Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.6.2.1. Autologous vaccines 7.5.6.2.2. Allogeneic vaccines 7.5.6.3. Indonesia Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.6.3.1. Tumour Cell Vaccines 7.5.6.3.2. Antigen/Peptide-based Vaccines 7.5.6.3.3. Dendritic Cell Vaccines 7.5.6.3.4. DNA Vaccines 7.5.6.3.5. RNA/mRNA-based Vaccines 7.5.6.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.6.3.7. Others 7.5.6.4. Indonesia Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.6.4.1. Hospitals 7.5.6.4.2. Hospital Pharmacies 7.5.6.4.3. Retail Pharmacies 7.5.6.4.4. Online Pharmacies 7.5.7. Malaysia 7.5.7.1. Malaysia Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.7.1.1. Addiction Vaccines 7.5.7.1.2. Autoimmune Disease Vaccines 7.5.7.1.3. Infectious Disease Vaccines 7.5.7.1.4. Neurological Disease Vaccines 7.5.7.2. Malaysia Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.7.2.1. Autologous vaccines 7.5.7.2.2. Allogeneic vaccines 7.5.7.3. Malaysia Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.7.3.1. Tumour Cell Vaccines 7.5.7.3.2. Antigen/Peptide-based Vaccines 7.5.7.3.3. Dendritic Cell Vaccines 7.5.7.3.4. DNA Vaccines 7.5.7.3.5. RNA/mRNA-based Vaccines 7.5.7.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.7.3.7. Others 7.5.7.4. Malaysia Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.7.4.1. Hospitals 7.5.7.4.2. Hospital Pharmacies 7.5.7.4.3. Retail Pharmacies 7.5.7.4.4. Online Pharmacies 7.5.8. Vietnam 7.5.8.1. Vietnam Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.8.1.1. Addiction Vaccines 7.5.8.1.2. Autoimmune Disease Vaccines 7.5.8.1.3. Infectious Disease Vaccines 7.5.8.1.4. Neurological Disease Vaccines 7.5.8.2. Vietnam Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.8.2.1. Autologous vaccines 7.5.8.2.2. Allogeneic vaccines 7.5.8.3. Vietnam Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.8.3.1. Tumour Cell Vaccines 7.5.8.3.2. Antigen/Peptide-based Vaccines 7.5.8.3.3. Dendritic Cell Vaccines 7.5.8.3.4. DNA Vaccines 7.5.8.3.5. RNA/mRNA-based Vaccines 7.5.8.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.8.3.7. Others 7.5.8.4. Vietnam Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.8.4.1. Hospitals 7.5.8.4.2. Hospital Pharmacies 7.5.8.4.3. Retail Pharmacies 7.5.8.4.4. Online Pharmacies 7.5.9. Taiwan 7.5.9.1. Taiwan Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.9.1.1. Addiction Vaccines 7.5.9.1.2. Autoimmune Disease Vaccines 7.5.9.1.3. Infectious Disease Vaccines 7.5.9.1.4. Neurological Disease Vaccines 7.5.9.2. Taiwan Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.9.2.1. Autologous vaccines 7.5.9.2.2. Allogeneic vaccines 7.5.9.3. Taiwan Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.9.3.1. Tumour Cell Vaccines 7.5.9.3.2. Antigen/Peptide-based Vaccines 7.5.9.3.3. Dendritic Cell Vaccines 7.5.9.3.4. DNA Vaccines 7.5.9.3.5. RNA/mRNA-based Vaccines 7.5.9.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.9.3.7. Others 7.5.9.4. Taiwan Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.9.4.1. Hospitals 7.5.9.4.2. Hospital Pharmacies 7.5.9.4.3. Retail Pharmacies 7.5.9.4.4. Online Pharmacies 7.5.10. Rest of Asia Pacific 7.5.10.1. Rest of Asia Pacific Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 7.5.10.1.1. Addiction Vaccines 7.5.10.1.2. Autoimmune Disease Vaccines 7.5.10.1.3. Infectious Disease Vaccines 7.5.10.1.4. Neurological Disease Vaccines 7.5.10.2. Rest of Asia Pacific Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 7.5.10.2.1. Autologous vaccines 7.5.10.2.2. Allogeneic vaccines 7.5.10.3. Rest of Asia Pacific Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 7.5.10.3.1. Tumour Cell Vaccines 7.5.10.3.2. Antigen/Peptide-based Vaccines 7.5.10.3.3. Dendritic Cell Vaccines 7.5.10.3.4. DNA Vaccines 7.5.10.3.5. RNA/mRNA-based Vaccines 7.5.10.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 7.5.10.3.7. Others 7.5.10.4. Rest of Asia Pacific Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 7.5.10.4.1. Hospitals 7.5.10.4.2. Hospital Pharmacies 7.5.10.4.3. Retail Pharmacies 7.5.10.4.4. Online Pharmacies 8. Middle East and Africa Therapeutic Vaccines Market Size and Forecast by Segmentation (in USD Billion) 2025-2034 8.1. Middle East and Africa Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 8.1.1. Addiction Vaccines 8.1.2. Autoimmune Disease Vaccines 8.1.3. Infectious Disease Vaccines 8.1.4. Neurological Disease Vaccines 8.2. Middle East and Africa Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 8.2.1. Autologous vaccines 8.2.2. Allogeneic vaccines 8.3. Middle East and Africa Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 8.3.1. Tumour Cell Vaccines 8.3.2. Antigen/Peptide-based Vaccines 8.3.3. Dendritic Cell Vaccines 8.3.4. DNA Vaccines 8.3.5. RNA/mRNA-based Vaccines 8.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 8.3.7. Others 8.4. Middle East and Africa Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 8.4.1. Hospitals 8.4.2. Hospital Pharmacies 8.4.3. Retail Pharmacies 8.4.4. Online Pharmacies 8.5. Middle East and Africa Therapeutic Vaccines Market Size and Forecast, by Country (2025-2034) 8.5.1. South Africa 8.5.1.1. South Africa Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 8.5.1.1.1. Addiction Vaccines 8.5.1.1.2. Autoimmune Disease Vaccines 8.5.1.1.3. Infectious Disease Vaccines 8.5.1.1.4. Neurological Disease Vaccines 8.5.1.2. South Africa Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 8.5.1.2.1. Autologous vaccines 8.5.1.2.2. Allogeneic vaccines 8.5.1.3. South Africa Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 8.5.1.3.1. Tumour Cell Vaccines 8.5.1.3.2. Antigen/Peptide-based Vaccines 8.5.1.3.3. Dendritic Cell Vaccines 8.5.1.3.4. DNA Vaccines 8.5.1.3.5. RNA/mRNA-based Vaccines 8.5.1.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 8.5.1.3.7. Others 8.5.1.4. South Africa Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 8.5.1.4.1. Hospitals 8.5.1.4.2. Hospital Pharmacies 8.5.1.4.3. Retail Pharmacies 8.5.1.4.4. Online Pharmacies 8.5.2. GCC 8.5.2.1. GCC Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 8.5.2.1.1. Addiction Vaccines 8.5.2.1.2. Autoimmune Disease Vaccines 8.5.2.1.3. Infectious Disease Vaccines 8.5.2.1.4. Neurological Disease Vaccines 8.5.2.2. GCC Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 8.5.2.2.1. Autologous vaccines 8.5.2.2.2. Allogeneic vaccines 8.5.2.3. GCC Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 8.5.2.3.1. Tumour Cell Vaccines 8.5.2.3.2. Antigen/Peptide-based Vaccines 8.5.2.3.3. Dendritic Cell Vaccines 8.5.2.3.4. DNA Vaccines 8.5.2.3.5. RNA/mRNA-based Vaccines 8.5.2.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 8.5.2.3.7. Others 8.5.2.4. GCC Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 8.5.2.4.1. Hospitals 8.5.2.4.2. Hospital Pharmacies 8.5.2.4.3. Retail Pharmacies 8.5.2.4.4. Online Pharmacies 8.5.3. Nigeria 8.5.3.1. Nigeria Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 8.5.3.1.1. Addiction Vaccines 8.5.3.1.2. Autoimmune Disease Vaccines 8.5.3.1.3. Infectious Disease Vaccines 8.5.3.1.4. Neurological Disease Vaccines 8.5.3.2. Nigeria Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 8.5.3.2.1. Autologous vaccines 8.5.3.2.2. Allogeneic vaccines 8.5.3.3. Nigeria Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 8.5.3.3.1. Tumour Cell Vaccines 8.5.3.3.2. Antigen/Peptide-based Vaccines 8.5.3.3.3. Dendritic Cell Vaccines 8.5.3.3.4. DNA Vaccines 8.5.3.3.5. RNA/mRNA-based Vaccines 8.5.3.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 8.5.3.3.7. Others 8.5.3.4. Nigeria Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 8.5.3.4.1. Hospitals 8.5.3.4.2. Hospital Pharmacies 8.5.3.4.3. Retail Pharmacies 8.5.3.4.4. Online Pharmacies 8.5.4. Rest of ME&A 8.5.4.1. Rest of ME&A Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 8.5.4.1.1. Addiction Vaccines 8.5.4.1.2. Autoimmune Disease Vaccines 8.5.4.1.3. Infectious Disease Vaccines 8.5.4.1.4. Neurological Disease Vaccines 8.5.4.2. Rest of ME&A Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 8.5.4.2.1. Autologous vaccines 8.5.4.2.2. Allogeneic vaccines 8.5.4.3. Rest of ME&A Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 8.5.4.3.1. Tumour Cell Vaccines 8.5.4.3.2. Antigen/Peptide-based Vaccines 8.5.4.3.3. Dendritic Cell Vaccines 8.5.4.3.4. DNA Vaccines 8.5.4.3.5. RNA/mRNA-based Vaccines 8.5.4.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 8.5.4.3.7. Others 8.5.4.4. Rest of ME&A Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 8.5.4.4.1. Hospitals 8.5.4.4.2. Hospital Pharmacies 8.5.4.4.3. Retail Pharmacies 8.5.4.4.4. Online Pharmacies 9. South America Therapeutic Vaccines Market Size and Forecast by Segmentation (in USD Billion) 2025-2034 9.1. South America Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 9.1.1. Addiction Vaccines 9.1.2. Autoimmune Disease Vaccines 9.1.3. Infectious Disease Vaccines 9.1.4. Neurological Disease Vaccines 9.2. South America Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 9.2.1. Autologous vaccines 9.2.2. Allogeneic vaccines 9.3. South America Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 9.3.1. Tumour Cell Vaccines 9.3.2. Antigen/Peptide-based Vaccines 9.3.3. Dendritic Cell Vaccines 9.3.4. DNA Vaccines 9.3.5. RNA/mRNA-based Vaccines 9.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 9.3.7. Others 9.4. South America Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 9.4.1. Hospitals 9.4.2. Hospital Pharmacies 9.4.3. Retail Pharmacies 9.4.4. Online Pharmacies 9.5. South America Therapeutic Vaccines Market Size and Forecast, by Country (2025-2034) 9.5.1. Brazil 9.5.1.1. Brazil Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 9.5.1.1.1. Addiction Vaccines 9.5.1.1.2. Autoimmune Disease Vaccines 9.5.1.1.3. Infectious Disease Vaccines 9.5.1.1.4. Neurological Disease Vaccines 9.5.1.2. Brazil Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 9.5.1.2.1. Autologous vaccines 9.5.1.2.2. Allogeneic vaccines 9.5.1.3. Brazil Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 9.5.1.3.1. Tumour Cell Vaccines 9.5.1.3.2. Antigen/Peptide-based Vaccines 9.5.1.3.3. Dendritic Cell Vaccines 9.5.1.3.4. DNA Vaccines 9.5.1.3.5. RNA/mRNA-based Vaccines 9.5.1.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 9.5.1.3.7. Others 9.5.1.4. Brazil Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 9.5.1.4.1. Hospitals 9.5.1.4.2. Hospital Pharmacies 9.5.1.4.3. Retail Pharmacies 9.5.1.4.4. Online Pharmacies 9.5.2. Argentina 9.5.2.1. Argentina Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 9.5.2.1.1. Addiction Vaccines 9.5.2.1.2. Autoimmune Disease Vaccines 9.5.2.1.3. Infectious Disease Vaccines 9.5.2.1.4. Neurological Disease Vaccines 9.5.2.2. Argentina Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 9.5.2.2.1. Autologous vaccines 9.5.2.2.2. Allogeneic vaccines 9.5.2.3. Argentina Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 9.5.2.3.1. Tumour Cell Vaccines 9.5.2.3.2. Antigen/Peptide-based Vaccines 9.5.2.3.3. Dendritic Cell Vaccines 9.5.2.3.4. DNA Vaccines 9.5.2.3.5. RNA/mRNA-based Vaccines 9.5.2.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 9.5.2.3.7. Others 9.5.2.4. Argentina Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 9.5.2.4.1. Hospitals 9.5.2.4.2. Hospital Pharmacies 9.5.2.4.3. Retail Pharmacies 9.5.2.4.4. Online Pharmacies 9.5.3. Rest Of South America 9.5.3.1. Rest Of South America Therapeutic Vaccines Market Size and Forecast, by Product (2025-2034) 9.5.3.1.1. Addiction Vaccines 9.5.3.1.2. Autoimmune Disease Vaccines 9.5.3.1.3. Infectious Disease Vaccines 9.5.3.1.4. Neurological Disease Vaccines 9.5.3.2. Rest Of South America Therapeutic Vaccines Market Size and Forecast, by Technology (2025-2034) 9.5.3.2.1. Autologous vaccines 9.5.3.2.2. Allogeneic vaccines 9.5.3.3. Rest Of South America Therapeutic Vaccines Market Size and Forecast, by Vaccine Type (2025-2034) 9.5.3.3.1. Tumour Cell Vaccines 9.5.3.3.2. Antigen/Peptide-based Vaccines 9.5.3.3.3. Dendritic Cell Vaccines 9.5.3.3.4. DNA Vaccines 9.5.3.3.5. RNA/mRNA-based Vaccines 9.5.3.3.6. Virus-like Particle (VLP) / Vector-based Vaccines 9.5.3.3.7. Others 9.5.3.4. Rest Of South America Therapeutic Vaccines Market Size and Forecast, by End-User (2025-2034) 9.5.3.4.1. Hospitals 9.5.3.4.2. Hospital Pharmacies 9.5.3.4.3. Retail Pharmacies 9.5.3.4.4. Online Pharmacies 10. Company Profile: Key Players 10.1. Sanofi-Pasteur 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Cytos Biotechnology AG 10.3. Intellect Neurosciences 10.4. Agenus Inc. 10.5. Celtic Pharma, 10.6. Novartis 10.7. Dendreon Corp. 10.8. Pfizer 10.9. Transgene 10.10. Antigenics 10.11. Argos Therapeutics 10.12. Bavarian Nordic 10.13. Biovest International 10.14. Celldex Therapeutics 10.15. Cel-Sci 10.16. Curevac 10.17. GlaxoSmithKline 10.18. Merck & Co. 10.19. Vaccinogen Inc. 10.20. Affiris 10.21. Medimmune, LLC 11. Key Findings 12. Industry Recommendations 13. Therapeutic Vaccines Market: Research Methodology 14. Terms and Glossary

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements